Sept. 5, 2003 — Caregivers of children treated with once or twice daily budesonide reported fewer limitations in daily activities and emotional functioning than caregivers of children treated with ...
Purpose: To evaluate the effectiveness of budesonide inhalation suspension relative to other common asthma therapies in a high-risk population, a study was conducted to compare the risk of having a ...
JERUSALEM--(BUSINESS WIRE)--Mar. 9, 2016-- Teva Pharmaceutical Industries Ltd. (NYSE: TEVA) today announced the launch of the generic equivalent to Pulmicort Respules®1 (budesonide inhalation ...
Please provide your email address to receive an email when new articles are posted on . Short-term budesonide transnasal nebulization effectively and safely treated patients with chronic ...
Aurobindo Pharma’s wholly-owned subsidiary company, Eugia Pharma Specialities Ltd, has received final approval from the US Food & Drug Administration (USFDA) to manufacture and market Budesonide ...
Teva Pharmaceutical Industries Ltd., a leading global pharmaceutical company, announced the launch of the generic equivalent to Pulmicort Respules (budesonide inhalation suspension), 1 mg/2 ml, in the ...
https://www.thehindubusinessline.com/markets/aurobindos-subsidiary-secures-approval-for-budesonide-inhalation-suspension/article67589939.ece Copy Aurobindo Pharma ...
Please provide your email address to receive an email when new articles are posted on . Twice-daily budesonide oral suspension, or BOS, improved outcomes in pediatric patients with eosinophilic ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results